에 대한 최신 뉴스 Immuneering (NASDAQ:IMRX) 주식

Immuneering

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

Immuneering Corporation - Class A Common Stock

Immuneering Corp

WIIM

SCNX

Scienture shares are trading higher after the company partnered with Kindeva to launch the 10mg REZENOPY nasal spray for opioid overdose treatment.

Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of $0.32 by 6.25 percent. The company reported quarterly sales of $3.44 million which missed the analyst consensus estimate of $3.53 million by 2.33 percent.

Earnings

Earnings Misses

News

SUNS

Sunrise Realty Trust Q4 Adj EPS $0.30 Misses $0.32 Estimate, Sales $3.44M Miss $3.53M Estimate

PSTV

Plus Therapeutics shares are trading higher after the company was granted FDA orphan drug designation for Rhenium Obisbemeda in leptomeningeal metastases in patients with lung cancer.

SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY&#xAE; (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.
Under the terms of the collaboration, Kindeva will manufacture and commercially supply REZENOPY&#xAE; (naloxone HCl) Nasal Spray 10mg. Scienture will own the new drug application (NDA) for REZENOPY&#xAE; in its name and be responsible for the sales, marketing and distribution of the product in the U.S. through Scienture's commercial operations infrastructure.
REZENOPY&#xAE; is the most potent (highest strength) version of naloxone HCl available in the market. The product leverages the proven use of the active ingredient and form factor, with increased effectiveness against potent opioids.
The addition of REZENOPY&#xAE; to Scienture's product portfolio aligns with Scienture's mission to provide innovative treatment solutions across therapeutic areas and expand access to patients. This product collaboration represents a strategic step in advancing public health initiatives and ensuring that life-saving interventions are readily available to those at risk of opioid overdose. As opioid-related fatalities continue to rise, Scienture is dedicated to collaborating with healthcare professionals, policymakers, and advocacy groups to enhance awareness, education, and distribution efforts.
Nasal delivery of Naloxone HCl has been widely recognized for its efficacy, ease of use, and accessibility, making it an essential tool for first responders, healthcare providers, and community programs. IQVIA data (MAT December 2024) indicates a total annual sales of $189 million, unit volume of $10.0 million (eaches) for Naloxone in the US market.

Government

Regulations

Scienture Partners with Kindeva to Launch 10mg REZENOPY Nasal Spray for Opioid Overdose Treatment, Secures Exclusive US Rights to FDA-Approved Spray

GBTG

Amex GBT Receives Approval From UK Competition And Markets Authority To Complete Its Acquisition Of CWT

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $200 price target.

Price Target

Reiteration

Analyst Ratings

AXSM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $200 Price Target

Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).
The SKNJCT-003 clinical study is currently underway in nine (9) clinical sites in United States and is expected to randomize 60 patients. The interim analysis was conducted after more than 50% of the targeted 60 patients in the study were randomized.
The interim analysis shows the clinical study SKNJCT-003 is trending positively with a proportion of subjects with complete clinical clearance of more than 60%. The analysis also shows the investigational product, D-MNA was well tolerated for both dose levels, a low-dose group receiving 100ug of D-MNA and a high-dose group receiving 200ug of D-MNA in all participants so far enrolled in the study, with no dose limiting toxicities (DLTs), or serious adverse events (SAEs). In addition, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examination. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed.
The Company plans to submit the interim analysis to the United States Food and Drug Administration (FDA) as part of a package seeking a Type C meeting with the FDA in Q2 2025. The purpose of the Type C meeting is to formally discuss the product development and gain further alignment on the clinical pathway. The Company's aim is to gain FDA's consent to fast-track the clinical development program.
"We are immensely encouraged by the positively trending interim analysis", stated Dr. Raza Bokhari, Executive Chairman &amp; CEO. "The interim analysis brings us one step closer to delivering a novel, non-invasive treatment for BCC".
Clinical Trial Design&nbsp;
The clinical study is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 60 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA.
The high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021. SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC.
The Company also has submitted a clinical design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH). The study is expected to randomize 36 patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi&nbsp;(CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).

MDCX

Medicus Pharma Reports Interim Results in Phase 2 Trial for Non-Invasive Skin Cancer Treatment,  Seeks FDA Meeting After Promising 60% Clearance Rate in Basal Cell Carcinoma Study

Smart Share Global Q3 Revenues $69.9M, Down 20% YoY

While the short interest on the outstanding shares of Michael Saylor&#8216;s Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) fell during its latest reporting period, implying a positive investor confidence, a mixed set of technical indicators highlighted the stock&#8217;s vulnerable position.
<h3 class="wp-block-heading">MSTR Short Interest Falls</h3>
The short interest on Strategy&#8217;s <a href="https://www.benzinga.com/25/03/44087250/strategys-saylor-calls-crypto-reserve-bullish-for-bitcoin-predicts-100-trillion-opportunity">stock</a> (formerly MicroStrategy) decreased during the last reporting period, falling from 24.01 million to 22.92 million shares. About 9.54% of the company&#8217;s publicly available shares were shorted as of the settlement date on Feb. 14, having an effective date of Feb. 26. 
According to Nasdaq <a href="https://www.nasdaq.com/market-activity/stocks/mstr/short-interest">data</a>, the short interest decreased by 4.53% from the previous settlement date of Jan. 31.
The average daily trading volume during the latest period increased from 18.10 million to 12.45 million shares. The volume indicated that it would require approximately 1.84 days for the short sellers to cover their positions without significantly impacting the stock price.
While high short interest signals bearishness; a decline indicates rising confidence. Hence, the 4.53% decline was a positive indicator.
<h3 class="wp-block-heading">Technical Analysis</h3>
Despite a reduction in the number of shorts, the technical indicators painted a mixed picture for the stock. As the stock closed at $308.55 apiece on Wednesday, it was clearly in a long-term uptrend, as it&#8217;s above its 200-day moving average of $234.93. Additionally, the stock showed short term bullishness by being above its eight- and 20-day moving averages.
However, it was below its 50-day moving average of $327.32 which indicated a potential intermediate-term weakness, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The relative strength index of 50.95 was in the neutral zone. But a negative MACD of -15.84 suggested a bearish momentum.
Thus, while long term trends are positive, recent momentum is negative.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06072101/MSTR-Technical-chart-1024x576.png" alt="" class="wp-image-812018" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06072101/MSTR-Technical-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06072101/MSTR-Technical-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06072101/MSTR-Technical-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06072101/MSTR-Technical-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06072101/MSTR-Technical-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/03/44160509/starlinks-european-rival-up-over-600-since-trump-halted-ukraine-aid-now-plans-to-replace-elon-musks-satellite-internet-service-in-war-torn-nation">Starlink&#8217;s European Rival, Up Over 600% Since Trump Halted Ukraine Aid, Now Plans To Replace Elon Musk&#8217;s Satellite Internet Service In War-Torn Nation</a>
Price Action: On Wednesday, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury company, MSTR rose 12.14% outpacing the gains in the exchange-traded fund tracking the Nasdaq 100 index, Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which rose 1.30%. In premarket on Thursday, MSTR was down 1.22%, whereas QQQ declined 1.25%.
The stock remains 2.85% higher on a year-to-date basis, however, it&#8217;s up 147.59% over a year.
<a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">Benzinga tracks 14 analysts</a> with an average price target of $494.93 for the stock, reflecting a &#8220;buy&#8221; rating. Estimates range widely from $140 to $690. Recent ratings from Barclays, Keefe, Bruyette &amp; Woods, and Maxim Group average at $493.67, suggesting a potential 61.290% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/MSTR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="388" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06071721/Strategy-ANR-1024x388.png" alt="" class="wp-image-812016" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06071721/Strategy-ANR-1024x388.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06071721/Strategy-ANR-300x114.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06071721/Strategy-ANR-768x291.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06071721/Strategy-ANR.png 1062w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44070799/mark-cuban-supports-trumps-new-gold-card-scheme-if-sold-to-corporations-for-employee-citizenship-have-a-look-at-the-listed-companies-with-most-number-of-immigrants">Mark Cuban Supports Trump&#8217;s New &#8216;Gold Card&#8217; Scheme If Sold To Corporations For Employee Citizenship: Here&#8217;re The Listed-Companies With Most Number Of Immigrants</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Market Summary

Technicals

Options

Markets

$BTC

MSTR

MSTR Short Interest Falls 4.53% But Technical Analysis Reveals Mixed Signals: Is Michael Saylor's Strategy Poised For A Bounce Back?

<a target="_blank" href="https://www.benzinga.com/topic/openai" rel="noreferrer noopener">ChatGPT parent</a> OpenAI could charge up to $20,000 monthly for specialized AI &#8220;agents,&#8221;&nbsp;the Information <a target="_blank" href="https://www.theinformation.com/articles/openai-plots-charging-20-000-a-month-for-phd-level-agents" rel="noreferrer noopener">reports</a>.
The Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) backed AI startup plans to launch several &#8220;agent&#8221; products tailored for different applications, including sorting and ranking sales leads and software engineering.
OpenAI plans to charge $2,000 monthly for a &#8220;high-income knowledge worker&#8221; agent and $10,000 monthly for a software developer agent.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/03/44140452/gm-stellantis-supplier-samsung-sdi-weighs-new-us-battery-plant-amid-trumps-ev-policy-shift" rel="noreferrer noopener">GM, Stellantis Supplier Samsung SDI Weighs New US Battery Plant Amid Trump&#8217;s EV Policy Shift</a>
OpenAI&#8217;s $20,000-per-month AI agent will likely support &#8220;PhD-level research.&#8221; Reportedly, OpenAI investor SoftBank (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) committed to spending $3 billion on OpenAI&#8217;s agent products in 2025.
OpenAI and Microsoft <a target="_blank" href="https://www.benzinga.com/news/24/10/41407196/openais-for-profit-structure-adds-valuation-complexity-to-microsoft-and-other-equity-investors-repor" rel="noreferrer noopener">reportedly negotiated how</a> to convert Microsoft&#8217;s $14 billion investment into equity amid OpenAI&#8217;s $157 billion valuation.
Both companies enlisted financial advisors to navigate the high-stakes discussions as OpenAI transitions to a for-profit model.
OpenAI&#8217;s projected computing expenses could reach $37.5 billion annually by 2029. OpenAI, whose&nbsp;monthly revenue hit&nbsp;$300 million in August, proposed increasing the chatbot&#8217;s price by 10% in 2024 and doubling it to $44 over the next five years.
Meanwhile, in China, Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) recently <a target="_blank" href="https://www.benzinga.com/25/02/44040003/alibaba-expands-ai-workforce-while-deepseek-slashes-model-prices-in-market-battle" rel="noreferrer noopener">introduced 3,000 internships</a>, half of which are in AI. It committed $52.2 billion in AI and cloud investment.
Alibaba&#8217;s move coincided with Chinese AI startup&nbsp;DeepSeek&#8217;s AI model price war, offering discounted off-peak pricing for developers. Chinese tech companies like&nbsp;Alibaba and its rivals were already&nbsp;engaged in a price war&nbsp;to win market share.&nbsp;
Price Action: MSFT stock is down 1.26% at $395.97 premarket at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44136859/asml-faces-uncertainty-as-us-sanctions-on-china-cut-demand-stock-down-24-in-12-months" target="_blank" rel="noreferrer noopener">Chip Equipment Maker ASML Faces Uncertainty As US Sanctions On China Impact Demand</a></li>
</ul>
Image via Shutterstock

Tech

Media

BABA

MSFT

SFTBF

SFTBY

ChatGPT Parent OpenAI's Specialized AI Agents Could Cost Up To $20 Thousand Per Month: report

Canaccord Genuity analyst David Hynes maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and lowers the price target from $385 to $320.

Canaccord Genuity Maintains Buy on MongoDB, Lowers Price Target to $320

Melinda French Gates credited a conversation with an IBM hiring manager for her decision to join Microsoft, a choice that significantly impacted her career and personal life.
What Happened: French Gates narrated her career-defining story to LinkedIn News. After two successful summer internships, she had a job offer from IBM on the table. However, a crucial conversation with her hiring manager led her to contemplate a different path, <a href="https://www.businessinsider.com/melinda-french-gates-ibm-hiring-manager-told-me-join-microsoft-2025-3">reported</a> Business Insider. &#8220;This little company, Microsoft. It was tiny,&#8221; she remembered saying. The manager&#8217;s response was, &#8220;If they give you an offer, you should take it.&#8221;
French Gates heeded the advice and joined Microsoft as a product manager in 1987, post her graduation from Duke University&#8217;s business school. She spent nearly ten years at Microsoft, rising to the designation of general manager and managing the company&#8217;s information products. She also met her ex-husband, Bill Gates, during this period in Microsoft.
After leaving Microsoft in 1996, French Gates co-founded the Gates Foundation with Bill Gates in 2000. She stepped away from the foundation in May and currently dedicates her efforts to Pivotal Ventures, the investment and incubation company she founded in 2015.
SEE ALSO: <a href="https://www.benzinga.com/general/market-summary/25/03/44160046/marvell-surpasses-ai-chip-sales-target-aims-higher-for-2026-but-stock-plunges-due-to-muted-guidance">Marvell Surpasses AI Chip Sales Target, Aims Higher For 2026, But Stock Plunges Due To Muted Guidance</a>
Why It Matters: While at Microsoft, French Gates can be credited for developing multimedia products like Microsoft Cinemania, Word, Publisher and Expedia.com. Her career trajectory is also marked by significant contributions to philanthropy. In 2024, she announced a <a href="https://www.benzinga.com/news/24/10/41298321/melinda-french-gates-pledges-250m-to-address-womens-biggest-needs-need-to-do-a-better-job">$250 million fund </a>to enhance women&#8217;s health, highlighting her primary focus post her tenure at the foundation.
Moreover, Warren Buffett, who was a trustee of the Gates Foundation, has expressed his admiration for French Gates. Buffett <a href="https://www.benzinga.com/news/24/11/42144671/warren-buffett-thinks-bill-gates-is-smart-as-hell-but-says-his-ex-wife-melinda-is-smarter-in-terms-of-seeing-the-whole-picture">praised her vision</a>, stating, &#8220;In terms of seeing the whole picture, she&#8217;s smarter.&#8221; He also referred to her as a &#8220;longtime friend.&#8221;
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/03/44065138/this-bill-gates-mistake-cost-microsoft-a-400-billion-opportunity-according-to-android-co-founder-sorry-bill">This Bill Gates &#8216;Mistake&#8217; Cost Microsoft A $400 Billion Opportunity, According To Android Co-Founder: &#8216;Sorry, Bill&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Melinda French Gates Reveals An IBM Manager Inspired Her To Join Bill Gates Co-Founded 'Little Company' Microsoft

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) with a Buy and maintains $20 price target.

CING

HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target

Tradeweb Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>), a leading, global operator of electronic marketplaces for rates, credit, equities and money markets, today reported total trading volume for the month of February 2025 of $50.3 trillion (tn)1. Average daily volume (ADV) for the month was $2.49tn, an increase of 33.1 percent (%) year-over-year (YoY). Excluding the impact of the ICD acquisition, which closed on August 1, 2024, total ADV for the month of February was up 18.2% YoY.
In February 2025, Tradeweb records included:
<ul>
<li>ADV in U.S. government bonds</li>
<li>ADV in fully electronic U.S. high yield credit</li>
<li>ADV in European credit</li>
</ul>
February 2025 Highlights
RATES
<ul>
<li>U.S. government bond ADV was up 21.3% YoY to $252.2 billion (bn). European government bond ADV was up 12.7% YoY to $57.4bn.
<ul>
<li>U.S. and European government bond activity remained strong in February. Record U.S. Treasuries ADV was led by record activity across the institutional and wholesale client channels, while European government bond ADV was driven by strong volumes across our institutional client channel. A diverse set of clients continued to trade on the platform, with growing adoption across a wide range of trading protocols.</li>
</ul>
</li>
<li>Mortgage ADV was up 21.0% YoY to $227.7bn.
<ul>
<li>To-Be-Announced (TBA) activity was primarily driven by strong roll volumes and increased trading activity from fast-money accounts. Tradeweb's specified pool platform reported strong volumes driven by a YoY increase in the number of clients executing on the platform.</li>
</ul>
</li>
<li>Swaps/swaptions ≥ 1-year ADV was up 0.2% YoY to $503.4bn and total rates derivatives ADV was up 9.9% YoY to $867.6bn.
<ul>
<li>Swaps/swaptions ≥ 1-year saw strong risk trading activity YoY driven by market volatility as a result of policy changes by the U.S. federal administration, as well as the recent election in Germany. This was partially offset by a 26% YoY decline in compression activity, which carries a relatively lower fee per million. 1Q25 compression activity as a percentage of swaps/swaptions ≥ 1-year is trending higher than 4Q24.</li>
</ul>
</li>
</ul>
CREDIT
<ul>
<li>Fully electronic U.S. credit ADV was up 11.8% YoY to $8.6bn and European credit ADV was up 24.6% YoY to $2.9bn.
<ul>
<li>U.S. credit volumes were driven by increased client adoption of Tradeweb protocols, most notably request-for-quote (RFQ) and Portfolio Trading. Tradeweb captured 17.8% and 7.3% of fully electronic U.S high grade and U.S. high yield TRACE, respectively, as measured by Tradeweb. Record European credit volumes were driven by further client adoption of Portfolio Trading, RFQ and Tradeweb AllTrade&#xAE; protocols. Automation adoption through AiEX continued to drive growth across U.S. and European credit.</li>
</ul>
</li>
<li>Municipal bonds ADV was up 26.9% YoY to $408 million (mm).
<ul>
<li>Municipal bond volumes saw growth across the retail and institutional platforms, outpacing the broader market, which was up approximately 9% YoY2.</li>
</ul>
</li>
<li>Credit derivatives ADV was up 67.6% YoY to $13.6bn.
<ul>
<li>Increased hedge fund and systematic account activity, along with heightened credit volatility, led to increased swap execution facility (SEF) and multilateral trading facility (MTF) credit default swaps activity.</li>
</ul>
</li>
</ul>
EQUITIES
<ul>
<li>U.S. ETF ADV was down 12.2% YoY to $7.7bn and European ETF ADV was up 23.5% YoY to $3.6bn.
<ul>
<li>European ETF volumes increased YoY as more clients embraced our automated rules-based RFQ protocol. U.S. ETF volumes were lower YoY primarily due to reduced SPY volumes in the market, which disproportionally impacted our U.S. ETF wholesale business.</li>
</ul>
</li>
</ul>
MONEY MARKETS
<ul>
<li>Repo ADV was up 30.1% YoY to $716.1bn.
<ul>
<li>Global repo trading activity was supported by increased client participation across the platform, driving record European repo activity. In the U.S., volumes were driven by the continued unwinding of the Fed's balance sheet and reduced balances in the reverse repo facility (RRP).</li>
</ul>
</li>
<li>Other Money Markets ADV was up YoY to $299.5bn.
<ul>
<li>Other money markets volume growth was driven by the inclusion of ICD volumes in February 2025.</li>
</ul>
</li>
</ul>

Tradeweb Reports $50.3T February Trading Volume, US Government Bonds ADV Jumps 21.3%, Credit Derivatives Surge 67.6% on Hedge Fund Activity

CRWD reverses early decline and rises over 18 points after the alert

<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/05211734/Screenshot-2025-03-05-at-4.17.10%E2%80%AFPM-999x1024.png" alt="" class="wp-image-7258" /></figure>
CrowdStrike Holdings, Inc. (CRWD) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:10 AM on March 6th, a significant trading signal occurred for CrowdStrike Holdings, Inc. (CRWD) as it demonstrated a Power Inflow at a price of $348.35. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in CrowdStrike&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in CrowdStrike&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for CRWD, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $348.35. The returns on the High price ($366.96) and Close price ($365.44) after the Power Inflow were respectively 5.3% and 4.9%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

CrowdStrike Stock Rises 5% After This Key Signal

Guidance

PACK

Ranpak Sees FY25 Revenue Growth Of 5% - 11%

Macro Economic Events

Econ #s

Economics

Challenger Job Cuts (Feb) 172.017K; Prior 49.795K

INMD

InMode Issues Response To Doma Perpetual's Letters; Clarifies Capital Allocation Strategy And Commitment To Shareholder Returns

Ranpak Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.04) by 150 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $105.00 million which beat the analyst consensus estimate of $100.41 million by 4.57 percent. This is a 16.15 percent increase over sales of $90.40 million the same period last year.

Earnings Beats

Ranpak Hldgs Q4 EPS $(0.10) Misses $(0.04) Estimate, Sales $105.00M Beat $100.41M Estimate

Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) sees FY2025 sales of $965.000 million-$1.000 billion vs $969.54 million analyst estimate.

PRTH

Priority Tech Holdings Sees FY2025 Sales $965.000M-$1.000B vs $969.54M Est

Press Releases

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Biotech

Health Care

General

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering Launches Pancreatic Cancer Advisory Board

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

CRGX

ONCY

RNXT

RPTX

TSX:ONC

Aadi Bioscience

Aligos Therapeutics

AlloVir

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CytomX Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

FibroBiologics

Forte Biosciences

Gain Therapeutics

ImmuCell

Immix Biopharma

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kala Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kezar Life Sciences

MAIA Biotechnology

OKYO Pharma

OSR Holdings

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Rein Therapeutics

Repare Therapeutics

Serina Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Xilio Therapeutics

Needham

Chardan Capital

Mizuho

Jefferies

Oppenheimer

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">개별 종목</a>에 대한 최신 뉴스를 확인할 수 있는 소스이다.
2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.
1. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>현재 가격: $121.44</li>
<li>52주 최고가/최저가: $39.23 ~ $140.76</li>
<li>연초 대비 수익률: +152.1%</li>
<li><a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple" target="_blank" rel="noopener" data-google-interstitial="false">6월</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow" target="_blank" rel="noopener" data-google-interstitial="false">7월</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noopener" data-google-interstitial="false">8월 </a>순위: 1위/2위/1위</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>현재 가격: $573.76</li>
<li>52주 최고가/최저가: $409.22 ~ $574.71</li>
<li>연초 대비 수익률: +21.4%</li>
<li>6월/7월/8월 순위: 3위/3위/2위</li>
</ul>
3. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>현재 가격: $261.63</li>
<li>52주 최고가/최저가: $138.80 ~ $271.00</li>
<li>연초 대비 수익률: +5.3%</li>
<li>6월/7월/8월 순위: 4위/1위/3위</li>
</ul>
4. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>현재 가격: $233.00</li>
<li>52주 최고가/최저가: $164.08 ~ $237.23</li>
<li>연초 대비 수익률: +25.5%</li>
<li>6월/7월/8월 순위: 5위/7위/6위</li>
</ul>
5. 휠러 리얼 에스테이트 인베스트 트러스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)
<ul>
<li>현재 가격: $8.09</li>
<li>52주 최고가/최저가: $2.90 ~ $1,126.80</li>
<li>연초 대비 수익률: -92.8%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
6. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>현재 가격: $488.07</li>
<li>52주 최고가/최저가: $342.35 ~ $503.52</li>
<li>연초 대비 수익률: +21.2%</li>
<li>6월/7월/8월 순위: 11위/11위/9위</li>
</ul>
7. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>현재 가격: $416.40</li>
<li>52주 최고가/최저가: $226.59 ~ $1,229.00</li>
<li>연초 대비 수익률: +45.9%</li>
<li>6월/7월/8월 순위: 10위/19위/4위</li>
</ul>
8. 갈메드 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>)
<ul>
<li>현재 가격: $6.86</li>
<li>52주 최고가/최저가: $2.73 ~ $23.80</li>
<li>연초 대비 수익률: +29.9%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
9. 인텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)
<ul>
<li>현재 가격: $23.46</li>
<li>52주 최고가/최저가: $18.51 ~ $51.28</li>
<li>연초 대비 수익률: -50.9%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
10. 인튜이티브 머신스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
<ul>
<li>현재 가격: $8.05</li>
<li>52주 최고가/최저가: $2.09 ~ $13.25</li>
<li>연초 대비 수익률: +241.1%</li>
<li>6월/7월/8월 순위: 20위 미만/20위 미만/20위</li>
</ul>
순위 밖의 주식들: 다음 주식들이 2024년 9월에 Benzinga Pro에서 11위에서 20위까지 가장 많이 검색된 종목들다.
11. 서밋 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)
12. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
13. 마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
14. 테논 메디컬 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>)
15. CN 에너지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>)
16. 취후오 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>)
17. 엔드라 라이프 사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>):
18. 어플라이드 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>)
19. 이뮤니어링 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>)
20. 트럼프 미디어 앤 테크놀로지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
중요성 (Why It's Important): 엔비디아는 9월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식으로 다시 한번 선정되었다. 이 주식은 2월 이후로 매달 1위 또는 2위를 기록하고 있으며, 때때로 SPY 또는 테슬라와 교대로 1위에 올랐다.
SPDR S&amp;P 500 ETF Trust는 9월에 S&amp;P 500 추적 지수가 사상 최고치를 기록하면서 2위를 차지했다.
테슬라는 7월에 1위를 차지한 이후 두 주 연속 3위를 기록했다. 이 주식은 2024년 동안 매달 검색된 상위 4개의 주식 중 하나로 자리 잡았다.
9월의 큰 관심은 신규 진입 주식들과 순위에서 떨어진 주식들이었다.
신규 진입자로는 휠러 리얼 에스테이트, 갈메드, 인텔 및 인튜이티브가 포함되었다. 이 4개 주식 중에서 인튜이티브만이 지난 3개월 간 상위 20위에 랭크된 바 있다. 이 신규 진입자들은 모두 지난달에 주식을 크게 변동시킨 촉매제가 있었다.
11위에서 20위까지의 목록에서도 이전 달과는 모든 주식이 달랐으며 인튜이티브는 상위 10위로 올라갔고, 팔란티어는 7위에서 12위로 하락했으며 나머지 주식들은 모두 상위 20위에 신규로 진입했다.
상위 20위의 하위 주식들 중 일부는 주가가 $5 이하로 거래되는 저가 주식들이며, 이들 주식은 큰 변동성을 보이며 Benzinga 트레이더들의 관심이 증가했다.
상위 20위에 이름 인지도로 들어온 큰 회사는 트럼프 미디어 앤 테크놀로지 그룹으로, 전 대통령 도널드 트럼프가 공동 설립자이다. 이 주식은 2024년 선거 주기 동안 매우 변동성이 컸다.
상위 10위에서 떨어진 주식들은 루멘 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>), 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), 지오백스 랩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) 및 앞서 언급한 팔란티어이다.
상위 20위에서 빠진 다른 큰 이름들은 8월에 13위였던 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)으로, 24위로 하락하여 리스트에 아슬아슬하게 들지 못했다.
메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)는 상위 20위에 자주 올라온 주식으로 8월에는 15위였으나 상위 20위에서 제외되었다.
전반적으로 9월에는 8월과 같은 상위 10개의 종목이 6개 있었고, 8월의 상위 20개 종목 중 8개가 포함되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/07/39603613/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-first-half-2024-where-do-nvidia-tesla-pala">독점: 2024년 상반기 가장 많이 검색된 종목 TOP 10 – 엔비디아, 테슬라, 팔란티어, 게임스탑의 순위는?</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Immuneering

뉴스

에 대한 최신 뉴스 Immuneering (NASDAQ:IMRX) 주식

수요일, 10월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌